Monoclonal Antibody to Sialic Acid Binding Ig Like Lectin 2 (CD22)
| Code | Size | Price |
|---|
| MAB144Hu21-20ul | 20ul | £89.00 |
Quantity:
| MAB144Hu21-100ul | 100ul | £167.00 |
Quantity:
| MAB144Hu21-200ul | 200ul | £225.00 |
Quantity:
| MAB144Hu21-1ml | 1ml | £518.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SIGLEC2; BL-CAM; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; T-cell surface antigen Leu-14
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG1 Kappa
Immunogen:
RPB144Hu01-Recombinant Sialic Acid Binding Ig Like Lectin 2 (CD22)
Item Name:
Sialic Acid Binding Ig Like Lectin 2
Potency (Clone Number):
C2
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Sialic Acid Binding Ig Like Lectin 2 (SIGLEC2) | RPB144Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||